Key points
At the G8 Summit in June 2013, science ministers focused on antimicrobial drug resistance
(i.e. anti-viral, anti-bacterial, anti-fungal and anti-parasite) strategies to stem the misuse of
antibiotics by optimizing doctor prescribing patterns to preserve the efficacy of existing antibiotics
against infections1
Antibacterial resistance has been a major health issue for over 10 years. The over prescription of
antibiotics for the common cold in children has significantly contributed to bacterial resistance
to antibiotics2
If the global spread of resistance is not slowed, this could have serious health implications
many common infections would become difficult or impossible to treat and routine surgical
procedures could become life-threatening3,4
In acne therapy, the widespread use of antibiotics has led to the increased prevalence of
Propionibacterium acnes (P. acnes) resistant strains worldwide and is a contributing factor to the
global antimicrobial resistance issue5,6
The emergence of antibacterial resistance via several mechanisms7 has resulted in treatment
failures, decreased response in acne patients8,9
Oral antibiotics are an important treatment option for more severe acne patients and at this time,
other alternatives such as oral isotretinoin are associated with severe side effects. However,
there are highly effective alternatives to
topical antibiotics
Responding to the urgent need to tackle this growing threat, guidelines have been issued calling
for responsible and appropriate use of antibiotics, including those used in acne therapy1,4,9
In dermatology, the issue of antibiotic resistance is of rising importance due to the growing number of
bacterial strains exhibiting resistance in acne therapy. Guidelines published by the Global Alliance to
Improve Outcomes in Acne, and endorsed by the American Academy of Dermatology (AAD) in 2014,
outline recommended treatment and management steps dermatologists can take to limit the growing
threat of antibiotic resistance9. Specifically mentioned is that oral and topical antibiotics should not be
used as monotherapy, yet 35% of oral antibiotics and 46% of topical antibiotics are currently prescribed
alone.12
Drug resistance has resulted largely from the extensive use of antibiotics in human and animal health as
well as in food production.3,4 Antibiotic overuse for the treatment of the common cold in children is
thought to be a significant factor contributing to the rapid rise in antibiotic resistant bacteria2 and
traditionally this has been the focus of governments for tackling the misuse of antibiotics. In 2004, further
authority attention was aimed at hospital-acquired bacterial infections as the spread of Methicillin-
resistant Staphylococcus aureus (MRSA) and Clostridium difficile became headline news in the UK.
Galderma Media Center, November 2014
For medical journalists outside the U.S. only
Measures put in place successfully reduced the number of MRSA and C. difficile cases by 84.7% and
53% respectively.4
The prevalence of antibiotic resistance is rising rapidly around the world, with virtually every area of the
globe affected.12 The problem is also expanding in scope, with increasing numbers of microbial strains
exhibiting resistance against a growing list of antibiotics.6 Left unaddressed, antibiotic resistance could
escalate into a global outbreak of previously treatable diseases and could increase the risk of routine
surgical procedures.10
Antibiotic resistance poses a major public health risk as it is associated with prolonged illness and
hospital stays, more complicated treatments and higher mortality rates.3,13 In Europe, the estimated
annual impact of antibiotic resistance is signficant:14
The use of antibiotics results in resistant bacteria surviving and reproducing, while susceptible strains get
eliminated.4,15 Over time, this has led to a gradually increasing spread of antibiotic-resistant bacterial
strains.4
Galderma Media Center, November 2014
For medical journalists outside the U.S. only
According to current guidelines, oral and topical antibiotics should not be used together to treat acne, yet
prescribing data indicates that 23% of oral antibiotic prescriptions continue to be combined with a topical
antibiotic.
Oral antibiotics continue to be an important treatment option for patients with moderate to severe acne.
Oral isotretinoin can be used in patients with severe acne but it may induce numerous serious side
effects such as teratogenicity (fetal malformation). However, there are alternatives to topical antibiotics
including topical retinoids and benzoyl peroxide (BPO). An important tactic to preserve the efficacy of
antibiotics is to ensure that oral antibiotics are only used for a limited time and not used in combination
with a topical antibiotic.16
Antibiotic resistance can have serious implications for patients and the wider community. For acne
patients, resistant P. acnes can result in failed treatments, with acne patients displaying decreased, poor
or no response to therapy, or possibly suffering relapses that may otherwise have been prevented.8,9 P.
acnes has also been rarely associated with more severe infections in conditions such as arthritis,18,19
endocarditis 20 and generally associated with surgeries, implants and immunocompromized patients.21 In
addition, bacteria present in other areas of the body, such as normal, protective flora present in the gut or
those carried as human commensals, may be submitted to changes due to antibiotic selection pressure.9
Contributing factors
The rapid rise of antibiotic resistance in acne therapy has been attributed to a number of factors:
Combination therapy should be started as early as possible, preferably at the initiation of treatment, to
simultaneously attack as many different pathogenic factors as possible.22
The key recommendations by the Global Alliance to Improve Outcomes in Acne, endorsed by the AAD in
2014, provides clear guidance on appropriate acne treatments which takes into account both the
physiopathology of acne, and the issue of antibiotic resistance.9
References
1. Group of Eight (2013). G8 science ministers statement London UK, 12 June 2013. Available at:
https://www.gov.uk/government/publications/g8-science-ministers-statement-london-12-june-2013 (date accessed: November
2014).
2. Nyquist A-C, Gonzales R, Steiner JF. Antibiotic prescribing for children with colds, upper respiratory tract infections, and
bronchitis. JAMA 1998;279(11):875877.
3. World Health Organization (2012). The evolving threat of Antibiotic resistance: options for action. Available at:
http://www.who.int/patientsafety/implementation/amr/publication/en/ (date accessed: November 2014).
4. Department of Health (2013). Annual report of the Chief Medical Officer, volume two, 2011:infections and the rise of
antimicrobial resistance. Available at:
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.p
df (date accessed: November 2014).
5. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004;64(21):23892397.
6. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol 2011;10(7):724733.
7. Todar K. Todars Online Textbook of Bacteriology. Available at: http://textbookofbacteriology.net/resantimicrobial_3.html (date
accessed: November 2014).
8. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad
Dermatol 1983;8:4145.
9. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to
Improve Outcomes in Acne Group. J Am Acad Dermatol 2009;60(Suppl 5):S150.
10. BBC news (2013). Antibiotics resistance as big a risk as terrorism medical chief. Available at:
http://www.bbc.co.uk/news/health-21737844 (date accessed: November 2014).
11. United States government. National Strategy For Combating Antibiotic-Resistant Bacteria, September 2014. Available at:
http://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf (date accessed November 2014)
12. Market Insights IMS D+J Market - MAT Q4 2012 - WW (39 Countries)
13. World Economic Forum (2013). The dangers of hubris on human health. Available at: http://reports.weforum.org/global-risks-
2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/ (date accessed: November 2014).
14. European Centre for Disease Prevention and Control and European Medicines Agency (2009). ECDC/EMEA Joint Technical
Report - The bacterial challenge: time to react. Available at:
http://www.emea.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf (date accessed: November
2014).
15. Tanghetti E. The impact and importance of resistance. Cutis 2007;80(Suppl1):59.
16. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003;206:5456.
17. Tzellos T, Zampeli V, Makrantonaki E, et al. Treating acne with antibiotic-resistant bacterial colonization. Expert Opin
Pharmaco 2011;12:12331247.
18. Levy PY, Fenollar F, Stein A, et al. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin
Infect Dis 2008;46:18841886.
19. Berthelot P, Carricajo A, Aubert G, et al. Outbreak of postoperative shoulder arthritis due to Propionibacterium acnes infection
in nondebilitated patients. Infect Control Hosp Epidemiol 2006;27:987990.
20. Delahaye F, Fol S, Celard M, et al. Propionibacterium acnes infective endocarditis. Study of 11 cases and review of literature.
Arch Mal Coeur Vaiss 2005;98:12121218.
21. Chanet V, Romaszko JP, Rolain JM, et al. Propionibacterium acnes adenitis. Presse Med 2005;34:10051006.
22. Gollnick H, Cunliffe W. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad
Dermatol 2003;49(Suppl 1):S137.